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Background: Regulation of tumor microenvironment is closely involved in the prognosis of Hodgkin lymphoma
(HL). Indoleamine 2,3-dioxygenase (IDO) is an enzyme acting as immune modulator through suppression of T-cell
immunity. This study aims to investigate role of IDO in the microenvironment of HL.
Methods: A total of 121 cases of HL were enrolled to do immunohistochemistry for IDO, CD163, CD68, CD4, CD8,
and FoxP3. Positivity was evaluated from area fractions or numbers of positive cells using automated image
analyzer. Correlations between IDO expression and various cellular infiltrates and clinicopathologic parameters were
examined and survival analyses were performed.
Results: IDO was expressed in histiocytes, dendritic cells and some endothelial cells with variable degrees, but not
in tumor cells. IDO positive cells were more frequently found in mixed cellularity type than other histologic types,
and in cases with EBV+, high Ann Arbor stages, B symptoms, and high IPS (all p < 0.05). High IDO expression was
associated with inferior survival (p < 0.001) and reflects an independent prognostic factor in nodular sclerosis HL.
Conclusions: This is the first study suggesting that IDO is the principle immunomodulator and is involved to
adverse clinical outcomes of HL.
Keywords: Hodgkin disease, Indoleamine-pyrrole 2,3-dioxygenase, Macrophages, Stromal cells, Tumor
microenvironment, Epstein-barr virus infections, PathologyBackground
The pathology of Hodgkin lymphoma (HL) is character-
ized by the relative paucity of tumor cells and an abun-
dance of reactive background cells. The composition and
frequencies of the reactive cellular milieu of HL varies con-
siderably among individual patients and histologic types
and at different stages throughout the course of the disease
[1]. As there has recently been a renewed interest in the
role of the tumor microenvironment, the reactive cells
in HL are now thought to be active participants in
tumor progression and immune escape [2]. The cellular* Correspondence: npol181@snu.ac.kr
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reproduction in any medium, provided the ormicromilieu of HL can be divided into two groups: in-
flammatory cells and stromal cells. Among these cells,
macrophages and T cells, particularly regulatory T cells
(Treg), have been consistently scrutinized in regard to
patient outcomes [2]. Although many studies regarding
the microenvironment of HL have been conducted over
the years, most of the regulatory mechanisms of Hodgkin
Reed Sternberg (HRS) cells on the surrounding tumor
microenvironment remain elusive due to the complex in-
teractions that occur among several soluble and cellular
factors.
Indoleamine 2,3-dioxygenase (IDO) is a tryptophan cata-
bolic enzyme that degrades tryptophan via the kynurenine
pathway [3]. This enzyme is involved in various patho-
physiological processes such as infection, autoimmunitytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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modulator produced by macrophages and dendritic cells,
and it suppresses T cell immunity through the inhibition
of effector T cell function and the induction of CD4 +
CD25 + FOXP3+ Tregs [5,6].
Until now, most studies regarding IDO were conducted
in an immunologic context such as the fields of transplant-
ation or autoimmunity, and little effort has been expended
on the role of IDO in the tumor microenvironment. Sev-
eral studies have reported that IDO expression correlates
with poor clinical outcome in some cancer types including
colorectal, endometrial, ovary and lung cancers and malig-
nant melanoma [7-10]. With regard to hematological ma-
lignancies, very few attempts have been made to elucidate
the effects of IDO on the tumor microenvironment. Ex-
cept for a few studies of diffuse large B-cell lymphomas,
the tumor microenvironment of HL has not yet been ex-
plored despite the importance of non-tumor components
in clinical outcome [11].
Here, we aimed to evaluate the role of IDO in the
microenvironment of HL. We have identified IDO positive
cells in HL tissue and analyzed its effects on the infiltra-
tion of other inflammatory cells, patients’ clinicopatho-
logic features and survival.
Methods
Patients
A total of 121 consecutive HL patients with available tissue
were enrolled in this study from the Boramae Medical
Center and the Seoul National University Hospital. Tissues
of these patients were collected from stored paraffin blocks
which were originally obtained at the time of initial diag-
nosis of HL. Histologic features and Epstein-Barr virus
(EBV) status were reviewed by two pathologists based on
the current WHO criteria. Clinical data including age, sex,
Ann Arbor stages, B symptoms, bulky disease, Human im-
munodeficiency virus (HIV) status, International prognos-
tic score (IPS), lactate dehydrogenase (LDH), initial blood
lymphocyte and monocyte counts, treatment response,
and survival data were obtained from electronic medical
records. This study was granted by the Institutional Review
Board of the Seoul National University Boramae Hospital.
Tissue microarray construction
Tissue microarray (TMA) blocks were manufactured for
immunohistochemistry (IHC). Two core tissues contain-
ing the most representative tumor areas (3 mm or 5 mm
in diameter) were taken from the individual donor blocks
and arranged into new recipient TMA paraffin blocks
using a trephine apparatus.
Immunohistochemistry (IHC)
Immunohistochemical staining for IDO (Millipore, Billerica,
MA, USA), CD68 (Dako, Carpinteria, California, USA),CD163 (Novocastra, Newcastle, UK), CD4 (Novocastra),
CD8 (Dako), and FOXP3 (Abcam, Cambridge, UK) was
performed on the TMA blocks following a standard
protocol using a Ventana Automated Immunostainer
(Ventana, Benchmark, Tuscan, AZ USA). After deparaf-
finization, heat-induced antigen retrieval was performed
using citrate buffer, pH 6.0 (CC1 protocol, Ventana). Re-
activity was detected using the Ultra-View detection kit
(Ventana).
Double IHC
To identify the lineage of IDO producing cells, double
IHC staining against IDO and CD68/CD163 was carried
out in the most representative cases of mixed cellularity
(MC) and nodular sclerosis (NS) subtypes. A peroxidase
system with 3,30-diaminobenzidine and hydrogen perox-
ide was applied for detection of the first primary antibody,
and an alkaline phosphatase system (Bond Polymer Refine
Red Detection, Leica, Wetzlar, Germany), for the second
primary antibody.
Automated image analysis
Semi-quantitative interpretation of IHC was performed
using automatic image analysis. Image J software (NIH
Image, Bethesda, MD, USA) was used to calculate the
area and number of positive cells with cytoplasmic
(IDO, CD68, CD163) and nuclear staining (FOXP3) pat-
terns. Aperio Image Analyzer software (Aperio, Vista,
CA, USA) was used to count cells with membranous
staining (CD4, CD8). The area of the frame used for the
counts was approximately 1 mm2 (996,944 μm2), and
multiple fields were sampled in the areas which exhib-
ited the richest HRS cell abundance. To standardize
tumor area and enable valid comparisons, all cores were
manually reviewed at the same time. The fraction of the
total area containing positive cells (a total area of
1 mm2) was calculated for IDO, CD68, or CD163, and
the number of positive cells was determined for CD4,
CD8, and FOXP3 staining.
Statistical analysis
Statistical analyses were performed using the Statistical
Package for Social Sciences software, version 20.0, for
Windows (IBM, IL, USA), and p values less than 0.05
were considered statistically significant based on a two-
sided statistical analysis. Non-parametric correlation be-
tween IDO expression and various cellular infiltrates was
tested via Spearman’s rho, and Mann–Whitney or Kruskal-
Wallis tests were used to compare groups with different
clinicopathologic variables. For survival analyses, patients
were divided into two groups according to the expression
of IDO and other cellular infiltrates. Cutoff values were
chosen either by maximum value of Youden’s index (J =
sensitivity + specificity-1) from the receiver-operating
Table 1 Demographics and the distribution of IDO
expression
Variable Total N (%)
IDO expression
Mean P-value
Age, years 121
<50 85 (70.2) 7.0 <0.001
≥50 36 (29.8) 20.2
Sex 121
Female 41 (33.9) 7.4 <0.001
Male 80 (66.1) 12.8
Histologic subtype 121
NLP 5 (4.1) 3.3 <0.001
NS 64 (52.9) 5.8
MC 46 (38.0) 19.2
LD 1 (0.8) 15.6
LR 1 (0.8) 1.1
Unclassifiable 4 (3.3) 8.9
Ann Arbor stage 115
I-II 66 (57.4) 6.9 0.004
III-IV 49 (42.6) 17.3
B symptoms 107
Yes 34 (31.8) 16.2 0.454
No 73 (68.2) 9.1
Bulky disease 104
Yes 8 (7.7) 11.8 0.826
No 96 (92.3) 11.8
IPS 116
≤2 82 (70.7) 7.5 0.013
>2 34 (29.3) 20.6
EBV status 96
Positive 43 (44.8) 17.4 0.069
Negative 53 (55.2) 8.7
HIV status 121
Positive 3 (2.5) 58.6 0.001
Negative 118 (97.5) 9.7
Treatment response 98
Success 65 (66.3) 10.0 0.098
Relapse 21 (21.4) 11.0
Progression 12 (12.2) 26.4
IDO, indoleamine 2,3-dioxygenase; NLP, nodular lymphocyte predominant; NS,
nodular sclerosis; MC, mixed cellularity; LR, lymphocyte-rich; LD, lymphocyte-depleted;
IPS, international prognostic score.
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ROC curves were not available. Survival time was defined
to be the period of time in months from the date of diag-
nosis to the date of death from any cause. Progression
time was defined as the period of time in months from
the date of diagnosis to the date at which progression of
disease was clinically identified by computed tomography
or positron emission tomography. Overall survival (OS)
and progression-free-survival (PFS) were compared using
the Kaplan-Meier method with a log-rank test. A multi-
variate Cox proportional hazards model with a backward
elimination was performed.
Results
Patient characteristics
Patients’ overall clinicopathologic characteristics and the
results of IHC are summarized in Table 1. The male to
female ratio was 2:1, and the age distribution was 10–80
years (mean = 38.2 years). Among 121 HL cases, there
were 5 nodular lymphocyte predominant (NLP), 64 NS,
46 MC, 1 lymphocyte-depleted, 1 lymphocyte-rich, and
4 unclassifiable cases. Forty-nine patients (42.6%) had
high Ann Arbor stages (defined as stage III or IV), and
approximately one third (31.8%) of all patients experi-
enced B symptoms. One third (29.4%) had high IPS
(≥3). EBV was detected in 43 of 96 cases (44.8%), and
HIV infection was observed in 3 patients. Most patients
received chemotherapy with standard ABVD regimen
(adriamycin, bleomycin, vinblastine, and dacarbazine)
with/without adjuvant radiotherapy. A few patients received
chemotherapy with MOPP regimen (nitrogen mustard, vin-
cristine, procarbazine, and prednisone) or radiotherapy
alone. Twenty-five of the 114 patients (22.2%) died
within the 7-year median follow-up period (range, 0.3 to
15.7 years). Twenty-one patients (21.4%) experienced
tumor relapse, and twelve (12.2%) had progressive disease.
IDO expression via IHC
IDO expression was observed in macrophages, dendritic
cells and vascular endothelial cells, but not in HRS cells
or lymphocytes (Figure 1). In double IHC assay, co-
localization of IDO and CD68, or IDO and CD163 was
demonstrated (Figure 2). The staining pattern of IDO
was largely cytoplasmic with focal nuclear staining in
some dendritic cells. The fraction of the area containing
IDO positive cells was variable and ranged from less
than 0.1% to 83.4% (median, 1.9%).
IDO expression and clinicopathologic variables
Associations between IDO expression and clinicopatho-
logic variables including bulky disease and B symptoms
are listed in Table 1. Patients with high IDO expression
correlated with advanced Ann Arbor stages (p = 0.004),
high IPS (p = 0.013), old age (p < 0.001) and male sex(p < 0.001). Regarding histologic types, nodular lympho-
cyte predominant HL displayed the lowest IDO expression
(mean area fraction = 3.3%), and the mixed cellularity type
exhibited the highest expression of IDO (mean = 19.2%).
The nodular sclerosis type also showed very low levels of
IDO expression (mean = 5.8%) (p < 0.001).
Figure 1 Representative features of immunohistochemistry in Hodgkin lymphoma (HL). (Inlet: an entire core tissue of tissue microarray)
IDO (indoleamine 2,3-dioxygenase) is highly expressed in macrophages, dendritic cells, and some endothelial cells, but not in Hodgkin Reed
Sternberg cells (HRS) or lymphocytes (A). CD68+ macrophages are found near HRS (B). CD163 is positive in both macrophages and some
dendritic cells (C). CD4+ (D), CD8+ (E), or FOXP3+ (F) T-cells are found in the background of HL.
Figure 2 Double immunohistochemistry with IDO and CD68/CD163 in classical Hodgkin lymphoma. Positive immunoreactivity of IDO
(red color) is colocalized with CD68 (A) or CD163 (B) (both, brown color) in the cytoplasm of macrophages or dendritic cells.
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expression (p = 0.069), and all three HIV-positive patients
showed extremely high IDO expression (mean = 58.6%)
(p = 0.001). In HIV-negative classical HL, EBV positive
cases showed significantly higher expression of IDO than
EBV-negative cases (p = 0.044, Additional file 1: Table S1).
IDO expression and cellular infiltrates
The results of the correlations between IDO expression
and various cellular infiltrates in classical HL (cHL) with
immunocompetent patients (excluding NLPHL and HIV
patients) are summarized in Table 2. Infiltration of CD163+
and CD68+ cells correlated with IDO expression (both
p < 0.001). Upon histologic examination, CD163 was
positive primarily in macrophages but also was present
in some dendritic cells; however, CD68+ cells were not
shown the dendritic feature in IHC staining. Therefore,
the fraction of the area containing CD163 positive cells
(median, 9.1%; range, 0.1%-92.2%) was higher than the
fraction of the area containing CD68 positive cells (me-
dian, 1.3%; range, 0.1%-28.2%). In addition, peripheral
blood monocyte counts at the time of initial diagnosis
also correlated with IDO (p = 0.015), CD163 (p = 0.035),
and CD68 (p = 0.011) expression.
Expression of IDO was positively correlated with the
number of CD8+ T cells (p < 0.001) and negatively corre-
lated with the number of CD4+ T cells (p = 0.020). Infil-
tration of FOXP3+ Treg cells did not correlate with IDO
expression (p = 0.795). However, the percentage of Treg
within CD4+ T cells (FoxP3/CD4+ ratio) correlated withTable 2 Correlation between IDO expression, cellular infiltrat
lymphoma
CD163 CD68 Mono
IDO
r 0.439 0.493 0.225
P-value <0.001 <0.001 0.026
CD163
r 0.668 0.179
P-value <0.001 0.107
CD68
r 0.229
P-value 0.044
Monocyte
r
P-value
CD8
r
P-value
CD4
r
P-value
FOXP3/CD4
r
P-value
Subtype
r
P-value
r, correlation coefficient; IDO, indoleamine 2,3-dioxygenase; EBV, Epstein-Barr virus;IDO in patients with limited disease status (stage I, II)
(p = 0.002).
Survival analysis
For univariate analyses, the patients were divided into
two groups according to the cutoff values of various cel-
lular markers. ROC curves were generated, areas under
the curve (AUCs) were measured for IDO, CD163, and
CD68, and the cutoff points were determined as 26%,
33%, and 5%, respectively. For the CD4, CD8, FoxP3/
CD4, and peripheral blood monocyte counts, median
values were chosen as the cutoff values because we were
unable to evaluate ROC curves and AUCs for these pa-
rameters. We analyzed the patients’ survival among the
cohort of HIV-negative classical HL (cHL), and also sep-
arately analyzed among NS and MC subtypes.
The results of the univariate survival analyses are sum-
marized in Table 3. Patients with high IDO expression,
frequent infiltration of CD163+ or CD68+ cells showed
significantly shortened OS (p < 0.001, p = 0.002, p = 0.058,
respectively) (Figure 3). The 5-year OS rate was much
lower for patients with high IDO positivity (67.8%) than
for those with low IDO positivity (91.7%). In a subgroup
analysis based on histologic types, high IDO expression
was associated with poor overall survival in both MC and
NS subtypes (both p = 0.017). In the multivariate analyses
among HIV- negative cHL cases, the effect of IDO on pa-
tients’ OS was not significant, although still trended to-
ward negative prognostic indicator (p = 0.111). However,
in NS subgroup, IDO was still an independent prognosticion and EBV positivity in HIV negative classical Hodgkin
CD8 CD4 FOXP3 /CD4 Subtype EBV
0.368 -0.200 0.210 0.433 0.158
<0.001 0.060 0.048 <0.001 0.150
0.194 0.102 -0.116 0.234 0.092
0.084 0.360 0.301 0.028 0.434
0.240 0.206 -0.084 0.197 0.118
0.034 0.069 0.461 0.072 0.328
0.109 -0.183 0.211 0.190 0.170
0.329 0.094 0.053 0.062 0.129
0.123 0.009 0.368 -0.103
0.264 0.936 <0.001 0.397
-0.788 -0.261 -0.197
<0.001 0.014 0.092
0.090 0.164
0.402 0.164
0.274
0.011
HIV, human immunodeficiency virus.
Table 3 Univariate survival analysis in HIV negative cHL patients
Variable
cHL MC subtype NS subtype
N OS PFS N OS N OS
Demographic data
Age ≥50 yrs 97 <0.001 0.753 40 <0.001 57 0.156
Male sex 97 0.197 0.132 40 0.496 57 0.816
Clinicopathologic data
IPS >2 94 0.025 0.046 38 0.029 56 0.964
Advanced stage 95 0.006 0.092 38 0.050 57 0.336
MC or NS subtype 97 0.012 0.144
B symptom 91 0.377 0.735 37 0.812 54 0.365
Bulky disease 91 0.046 0.576 36 0.017 55 0.422
EBV infection 78 0.045 0.971 31 0.395 47 0.217
PB monocyte (≥7.1%) 90 0.652 0.402 35 0.813 55 0.076
Immunohistochemical data
IDO (≥26%) 97 <0.001 0.828 40 0.017 57 0.017
CD163 (≥33%) 77 0.002 0.958 31 0.015 46 0.137
CD68 (≥5%) 73 0.058 0.314 29 0.078 44 0.536
CD4 (≥301 cells/mm2) 79 0.916 0.684 34 0.407 45 0.761
CD8 (≥2302 cells/mm2) 76 0.813 0.527 33 0.361 43 0.758
FOXP3/CD4 (≥0.5) 79 0.313 0.835 34 0.167 45 0.843
HIV, human immunodeficiency virus; cHL, classical Hodgkin lymphoma; N, number; OS, overall survival; PFS, progression free survival; IPS, international prognostic
score; MC, mixed cellularity; NS, nodular sclerosis; PB, peripheral blood; IDO, indoleamine 2,3-dioxygenase.
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independent prognostic factors in HIV- negative cHL
(p < 0.001, p = 0.046, respectively) (Table 4).
Discussion
This is the first study to investigate the association of IDO
expression with clinicopathologic characteristics of HL.
We confirmed that IDO was positive in the background
stromal cells of HL to a variable degree and that high ex-
pression of IDO was a significant prognostic predictor of
unfavorable outcome in HL. Our results also provide a ra-
tionale for the development of novel therapeutic strategiesFigure 3 Survival plots of classical Hodgkin lymphoma tested by Kap
expression was associated with poor overall survival in HIV-negative classical H
or dendritic cells represented by CD163 (B) or CD63 (C) was associated withtargeting the tumor microenvironment, including immune
cells, to achieve an optimal outcome in HL.
The understanding of the influence of cellular com-
ponents on the clinical course of HL has progressively
emerged over the last few years. Although the precise
mechanisms required for these cells to orchestrate neo-
plastic and inflammatory reactions are not entirely under-
stood, progress has been made by many researchers [12].
Recent studies have revealed that the tumor microenviron-
ment (e.g., macrophage infiltration) is a major determinant
of poor clinical outcome [12-16]. Our study results are in
agreement with previous studies showing that macrophagelan-Meier method according to IDO expression. High IDO
odgkin lymphoma patients. (A). In addition, Infiltration of macrophages
adverse outcome.
Table 4 Multivariate survival analysis in classical Hodgkin lymphoma patients
Variable
HIV- cHL HIV- MC subtype HIV- NS subtype
P HR (95% CI) P HR (95% CI) P HR (95% CI)
Age ≥50 years <0.001 6.837 (2.588-18.062) 0.009 15.669 (1.995-123.042) 0.915 0.888 (0.099-7.967)
Advanced stage 0.403 1.584 (0.539-4.652) 0.329 2.263 (0.440-11.654) 0.141 3.382 (0.669-17.095)
Bulky disease 0.040 3.822 (1.060-13.783) 0.051 5.146 (0.991-26.725) 0.646 1.732 (0.166-18.091)
Blood monocyte 0.111 0.906 (0.802-1.023) 0.100 0.860 (0.719-1.029) 0.009 0.640 (0.459-0.894)
IDO 0.111 1.018 (0.996-1.040) 0.378 1.011 (0.98601.037) 0.001 1.104 (1.043-1.168)
CD163 0.812 1.002 (0.982-1.023) 0.439 1.008 (0.987-1.030) 0.020 1.061 (1.009-1.116)
CD68 0.636 0.970 (0.854-1.101) 0.906 0.992 (0.872-1.129) 0.735 1.056 (0.772-1.443)
HR, hazard ratio; CI, confidential interval; HIV, human immunodeficiency virus; cHL, classical Hodgkin lymphoma; HR, hazard ratio; CI, confidential interval; IDO,
indoleamine 2,3-dioxygenase.
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focused on the role of IDO secreted by stromal macro-
phages or dendritic cells on the clinicopathologic char-
acteristics of HL.
In this retrospective review of 121 HL patients, we have
shown that IDO expression was significantly higher in
mixed cellularity subtype cases and HIV or EBV positive
cases. Moreover, expression of IDO significantly corre-
lated with old age, advanced Ann Arbor stage, and high
IPS (Table 5). Overall, cases with high IDO expression
corresponded to cases with relatively low immunity. IDO
is involved in the production of immunomodulatory tryp-
tophan metabolites that contribute to immunosuppression
and immune tolerance. The cellular sources and the func-
tion of IDO are consistent with our findings.
In our study, high IDO expression correlated with de-
creased CD4+ T cells and increased CD8+ T cells, and in-
creased ratio of FoxP3/CD4 in HL of limited stages. This
finding is partly consistent with previous reports, which
suggest that tumors expressing high IDO had decreased
numbers of tumor-infiltrating lymphocytes or increased
numbers of FOXP3+ regulatory T cells (Treg) [7]. Also,
Elpek et al. reported Treg dominated immune evasion inTable 5 Characteristics of Hodgkin lymphoma patients
according to IDO expression
Variable IDO high IDO low
Sex Male Female
Age group Older Young
Histologic type MC, LD, LR NLP, NS
Ann Arbor stages Advanced stage Limited stage
IPS High Low
B symptom Present Absent
EBV or HIV infection positive Not accompanied
FOXP3/CD4* High Low
*FoxP3/CD4 significantly correlated with IDO in cases with limited stages.
IDO, indoleamine 2,3-dioxygenase; MC, mixed cellularity; LD, lymphocyte-depleted;
LR, lymphocyte-rich; NLP, nodular lymphocyte predominant; NS, nodular sclerosis;
IPS, international prognostic score.early stage B-cell lymphoma but not in late stage tumor
[17]. Possibly, more complicated and various immune
evasion mechanisms might exit in the microenvironment
of advanced tumors. We hypothesize that the impairment
of T cell immunity triggered by IDO contributes to the
imbalance in the CD4/CD8 ratio and recruitment of Treg
in HL. Further evaluation is needed to elucidate these
mechanisms.
Currently, studies regarding the association between
IDO and viral infection in tissue samples have rarely
been attempted. In our study, IDO expression in EBV-
or HIV-associated HL was considerably high. This find-
ing merits some interpretation regarding the known
characteristics of EBV or HIV infection in HL. Infection
of EBV in East Asian HL patients occurs more fre-
quently than in Western countries and is reported to be
associated with a poor prognosis [18]. Activation of the
transcription factor nuclear factor-kappa B (NF-kB) by
EBV is known to be responsible for various immuno-
logic changes in HL [19]. Paolo et al. suggested that
non-canonical NF-kB activation is necessary for the in-
duction of IDO expression [5]. Recently, Song et al.
showed that EBV-induced IDO metabolites provide a
potential mechanism by which EBV escapes immune at-
tack by NK cells [20]. In addition, Manches et al. have
reported that activation of NF-kB in HIV patients in-
duces IDO expression in dendritic cells [21]. Therefore,
correlation between EBV or HIV positivity and IDO ex-
pression in our results is explainable. It is noteworthy
that all three HIV +HL in our series showed strikingly
high IDO positivity. In HIV-negative cHL, EBV positivity
was strongly associated with high expression of IDO, es-
pecially in MC subtypes. However, the overall expression
level of IDO was very low regardless of EBV infection in
NS subtype. Therefore, we suppose that IDO participates
more significantly in the construction of microenviron-
ment through recruitment of inflammatory cells rather
than EBV does.
Over the past few years a considerable number of studies
have been conducted on the prognostic effects of tumor
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solid tumors and hematolymphoid malignancies. We also
observed that high infiltration of CD163+ macrophages
and IDO were adverse prognostic factors of patient OS in
univariate analysis. We separated groups of high IDO or
histiocytes based on the cutoff values generated from
ROC curves of automated analysis. However, the cutoff
values we have chosen can be changed in other cohorts
using conventional way of immunohistochemical assess-
ment. Through the use of multivariate analysis, only IDO
retained its statistical significance of negative prognostic
indicator among total cohort (Additional file 2: Table S2),
although the statistical power was weakened when con-
fined in HIV-negative cHL. Therefore, we suspect that the
prognostic impact of tumor associated macrophages on
HL largely originates from the cells’ ability to secrete IDO.
Our results are in agreement with many earlier studies
which reported that IDO correlated with less favorable
clinical outcomes.
The alleged protean immunomodulator IDO is now
popularly recognized as an important factor in the tumor
microenvironment for cancer immunity. Taken together,
our findings provide evidence that IDO plays an import-
ant role in the microenvironment of HL.Conclusions
In summary, IDO was often highly expressed in the stro-
mal cells of HL and correlated with poor prognostic fac-
tors, in addition to EBV or HIV infection. High expression
of IDO was a significant negative predictor of patients’
survival. Our results provide evidence that IDO is a major
immune modulator of HL.Additional files
Additional file 1: Table S1. Association of EBV infection and
clinicopathologic variables in HIV-negative classical Hodgkin lymphoma
(HIV- cHL).
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